{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Rockford",
      "state": "IL",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "79977",
      "recalling_firm": "Mylan Institutional, Inc. (d.b.a. UDL Laboratories)",
      "address_1": "1718 Northrock Ct",
      "address_2": "N/A",
      "postal_code": "61103-1201",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the U.S.",
      "recall_number": "D-0822-2018",
      "product_description": "Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-902-20",
      "product_quantity": "1,065 blister cards of 100 capsules each",
      "reason_for_recall": "GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination",
      "recall_initiation_date": "20180501",
      "center_classification_date": "20180522",
      "termination_date": "20210310",
      "report_date": "20180530",
      "code_info": "Lot #: 3090454, Exp. 03/2019"
    }
  ]
}